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adverse events). In a multivariate analysis the variables associ-
ated with satisfaction were: ß2 agonist (p = 0.071) and males 
(p = 0.051). CONCLUSIONS: Patient satisfaction with COPD
treatment is high and is related with the low frequency of adverse
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OBJECTIVES: To estimate the cost of red blood cell (RBC)
transfusion using three different techniques, i.e. allogeneic trans-
fusion, autologous transfusion and perioperative auto-transfu-
sion, from a societal perspective for Sweden. METHODS: Data
concerning the sequence of procedures involved in the collection,
preparation and transfusion of RBCs and perioperative auto-
transfusion was collected from the Swedish National Board of
Health and Welfare, from other published sources and from
interviews with staff at ﬁve large Swedish hospitals. Direct hos-
pital costs were derived from the Southern Regional Health Care
Board and from Haemonetics Scandinavia AB. Income data on
hospital staff was derived from the Swedish federation of county
councils. Data for estimating indirect costs have been obtained
from Statistics Sweden and the National Tax Board of Sweden.
RESULTS: The cost of a 2-unit transfusion was found to be
SEK7 144 (€792) for ﬁltered allogeneic RBCs and SEK5
394(€598) for autologous RBCs for surgery patients. Transfu-
sion reactions accounted for more than 40 percent of the costs
of allogeneic RBC transfusions. The administration cost was
found to be much higher for autologous transfusions compared
to allogeneic transfusions. The cost of intraoperative erythrocyte
salvage was calculated to be SEK2567 (€285) per transfusion (>4
units). Of the three available techniques, allogeneic RBC trans-
fusion is the most common method used in Sweden. More than
99% of all donated blood is allogeneic in the case of Sweden.
CONCLUSIONS: Patients who suffer from anaemia have the
option of treatment with blood transfusion or treatment with
erythropoietic stimulating agents. From a societal perspective,
allogeneic RBC transfusions are considerably more costly than
the perceived cost at the hospitals. Allogeneic transfusion were
found to be more costly than autologous transfusions concern-
ing transfusion reactions but less costly with respect to adminis-
tration at the blood centres.
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OBJECTIVES: To estimate the cost-effectiveness of remifen-
tanil/propofol versus fentanyl/propofol as regimen of total intra-
venous anesthesia using infusion pump in Mexican Health
Sector. METHODS: An expert panel with anesthesiologists was
established to identify the medical and non-medical health
resources used to perform a general anesthesia in patients with
65kg, ASA I (American Society of Anesthesiologists) for a range
in the anesthetic time from 60 to 180 minutes and the effective-
ness accomplished with the regimens. The information gathered
from the expert panel was completed with a literature review.
Ofﬁcial unitary costs for the Mexican Institute of Social Security
(IMSS) and Hospitals from The Ministry of Health were used.
The expected cost per patient included the costs of drugs, post-
anesthetic care unit, labor costs and costs associated with adverse
events. Costs were expressed in Mexican Pesos and then con-
verted to US dollars (rate exchange 11 Mexican pesos = 1USD).
RESULTS: For the remifentanil/propofol regimen the induction
doses were 1mcg/kg remifentanil and 2mg/kg propofol; the
maintenance doses were 0.5mcg/kg/min remifentanil and 85
mcg/kg/min. For the fentanyl/propofol group the induction doses
were 3mcg/kg fentanyl and 2mg/kg propofol; the maintenance
doses were 3mcg/kg/hour fentanyl and 120mcg/kg/min. For the
median of anesthetic time, 120 minutes, the costs per anesthesia
were $1421 (129 USD) and $1644 (149 USD) for the remifen-
tanil/propofol and fentanyl/propofol regimen, respectively. The
average extubation time was 7 minutes for the regimen with
remifentanil, and 15 minutes with fentanyl. Using a visual ana-
logue scale, where 0 represents the worst value and 10 the best,
the remifentanil/propofol regimen was graded 9.6 and the fen-
tanyl/propofol 8.6. CONCLUSIONS: Regimens with remifen-
tanil/propofol dominates fentanyl/propofol techniques, since
they provide a highly effective and secure anesthesia and also
represents a signiﬁcant saving in total resources used (mainly in
use of propofol and post-anesthetic care unit) offsetting its higher
acquisition costs.
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OBJECTIVE: To evaluate cost of antibiotic therapy in patients
undergoing colorectal surgery and possible inﬂuence of post-
surgical infections on hospital costs. METHODS: We conducted
a naturalistic, retrospective study, collecting data from medical
records on patients undergoing surgery in 2002–2004, from two
Italian hospitals. Analyses were conducted from the hospital’s
point of view: cost of treatment (expressed as €/hospitalization,
values of 2005) and length of post-surgical stay as a proxy of
hospital cost are reported, with comparisons among the two hos-
pitals (HOSP1 and HOSP2). The bootstrap resampling method
(5000 samples) was applied to have more reliable results.
RESULTS: Data of 174 patients (mean age 68.3, 38–93 years,
49.4% men) was collected: 82.8% underwent surgery for malig-
nant cancer, 2.3% for benign cancer, 14.9% for other reasons.
Antibiotic therapy was applied by adopting two different guide-
lines: in HOSP1 patients were treated with 5-nitroimidazole 
and ceftazidime or cefotassime. If infections occurred,
cephalosporins, ﬂuoroquinolones, quinolones, carbapenems,
penicillines were used, according to the type of infections.
Patients from HOSP2 were preventively treated with: cefotetan
or cefoxitine, or 5-nitroimidazole + gentamicine or piperacilline
+ 5-nitroimidazole. The infected patients were treated with car-
bapenems, penicillines, cephalosporins, triazoles, amynoglico-
sides, and ﬂuoroquinolones. Thirty-eight patients (22%) were
infected, with similar frequencies in the two hospitals. Therapy
cost on average €140.59 (€0.0–816.13), with signiﬁcant differ-
ence between non infected and infected patients (97.24 vs.
€293.99, p < 0.0001). The average cost was higher in HOSP1
(€182.45 vs. €102.40, p < 0.001) while the median post-surgical
